Journal of Medical Ethics 46 (7):465-469 (2020)
Abstract |
Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines.
|
Keywords | No keywords specified (fix it) |
Categories | (categorize this paper) |
DOI | 10.1136/medethics-2020-106235 |
Options |
![]() ![]() ![]() ![]() |
Download options
References found in this work BETA
Vulnerability in Research and Health Care; Describing the Elephant in the Room?Samia A. Hurst - 2008 - Bioethics 22 (4):191–202.
Social Value, Clinical Equipoise, and Research in a Public Health Emergency.Alex John London - 2019 - Bioethics 33 (3):326-334.
Vulnerability: Too Vague and Too Broad?Doris Schroeder & Eugenijus Gefenas - 2009 - Cambridge Quarterly of Healthcare Ethics 18 (2):113.
The Health Impact Fund: A Useful Supplement to the Patent System?Aidan Hollis - 2008 - Public Health Ethics 1 (2):124-133.
Citations of this work BETA
COVID-19 Current Controversies.Jennifer Blumenthal-Barby - 2020 - Journal of Medical Ethics 46 (7):419-420.
Similar books and articles
A New Vaccine for Tuberculosis: The Challenges of Development and Deployment. [REVIEW]Helen A. Fletcher, Tony Hawkridge & Helen McShane - 2009 - Journal of Bioethical Inquiry 6 (2):219-228.
Ethical Issues in the Development and Testing of a Preventive Hiv Vaccine.Christine Grady - 1993 - Dissertation, Georgetown University
Hiv Vaccine Trials: Reconsidering the Therapeutic Misconception and the Question of What Constitutes Trial Related Injuries.Udo Schüklenk & Richard Ashcroft - 2007 - Developing World Bioethics 7 (3):ii–iv.
VO: Vaccine Ontology.Yongqun He, Lindsay Cowell, Alexander D. Diehl, H. L. Mobley, Bjoern Peters, Alan Ruttenberg, Richard H. Scheuermann, Ryan R. Brinkman, Melanie Courtot, Chris Mungall, Barry Smith & Others - 2009 - In ICBO 2009: Proceedings of the First International Conference on Biomedical Ontology. Buffalo:
Prioritising Healthcare Workers for Ebola Treatment: Treating Those at Greatest Risk to Confer Greatest Benefit.Priya Satalkar, Bernice E. Elger & David M. Shaw - 2015 - Developing World Bioethics 15 (2):59-67.
Ethical Tradeoffs in Trial Design: Case Study of an HPV Vaccine Trial in HIV‐Infected Adolescent Girls in Lower Income Settings.J. C. Lindsey, S. K. Shah, G. K. Siberry, P. Jean-Philippe & M. J. Levin - 2013 - Developing World Bioethics 13 (2):95-104.
Ethics, Human Rights and HIV Vaccine Trials in Low-Income Settings: Table 1.Leslie London, Ashraf Kagee, Keymanthri Moodley & Leslie Swartz - 2012 - Journal of Medical Ethics 38 (5):286-293.
Preventing Sin: The Ethics of Vaccines Against Smoking.Sarah R. Lieber & Joseph Millum - 2013 - Hastings Center Report 43 (3):23-33.
An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights From the HPV Vaccine in Canada.Ana Komparic, Maxwell J. Smith & Alison Thompson - 2016 - Public Health Ethics 9 (1):78-91.
Hiv Preventive Vaccine Research: Selected Ethical Issues.Christine Grady - 1994 - Journal of Medicine and Philosophy 19 (6):595-612.
Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking.Anna Wolters, Guido de Wert, Onno C. P. van Schayck & Klasien Horstman - 2016 - Public Health Ethics 9 (2):183-197.
Convergent Ethical Issues in HIV/AIDS, Tuberculosis and Malaria Vaccine Trials in Africa: Report From the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre Consultation, 10-11 February 2009, Durban, South Africa. [REVIEW]Nicole Mamotte, Douglas Wassenaar, Jennifer Koen & Zaynab Essack - 2010 - BMC Medical Ethics 11 (1):3-.
Ethically Compromised Vaccines in Australia.Kerri Anne Brussen - 2012 - Chisholm Health Ethics Bulletin 17 (3):1.
Stakeholder Views of Ethical Guidance Regarding Prevention and Care in HIV Vaccine Trials.Rika Moorhouse, Catherine Slack, Michael Quayle, Zaynab Essack & Graham Lindegger - 2014 - BMC Medical Ethics 15 (1):51.
Ethical Considerations in International HIV Vaccine Trials: Summary of a Consultative Process Conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS).D. Guenter - 2000 - Journal of Medical Ethics 26 (1):37-43.
Analytics
Added to PP index
2020-05-16
Total views
23 ( #495,128 of 2,518,140 )
Recent downloads (6 months)
1 ( #408,577 of 2,518,140 )
2020-05-16
Total views
23 ( #495,128 of 2,518,140 )
Recent downloads (6 months)
1 ( #408,577 of 2,518,140 )
How can I increase my downloads?
Downloads